A Child with Prostaglandin I2-associated Thyrotoxicosis: Case Report
J Clin Res Pediatr Endocrinol
; 11(2): 207-210, 2019 05 28.
Article
in En
| MEDLINE
| ID: mdl-30325337
ABSTRACT
Prostaglandin I2 (PGI2) causes hyperthyroidism, a critical complication in patients with pulmonary arterial hypertension (PAH). However, it remains unknown whether PGI2 may have unfavorable effects on thyroid function in children with congenital portosystemic venous shunt syndrome (CPSVS). We present a boy with CPSVS who developed PAH at seven years of age. During ongoing PGI2 therapy, he experienced thyrotoxicosis at 17 years of age. The literature review showed that the reported 12 patients with PAH (median 11 years of age) developed hyperthyroidism during between one and 11 years of PGI2 treatment. Only one patient survived the acute PAH crisis due to hyperthyroidism. These data provide evidence that prophylactic intervention for hyperthyroidism is indicated for children with CPSVS during PGI2 treatment.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Thyrotoxicosis
/
Epoprostenol
/
Vascular Malformations
/
Hypertension, Pulmonary
/
Antihypertensive Agents
Type of study:
Prognostic_studies
/
Risk_factors_studies
Limits:
Humans
/
Male
/
Newborn
Language:
En
Journal:
J Clin Res Pediatr Endocrinol
Year:
2019
Document type:
Article
Affiliation country:
Japan